Background: Triple Negative Breast Cancers (TNBC) account for 15% of all breast cancer and are
one of the most aggressive type and have poor long-term prognosis. Moreover, there
are currently no approved targeted therapies and chemotherapy remains the mainstay
of treatment for early and advanced disease. The level of immune infiltrate in TNBC
has been linked to a more favourable outcome and lower mutation and neoantigen counts,
indicating that an active immune surveillance is ongoing and that these patients might
benefit form a combination of checkpoint inhibitor therapy and antigen specific vaccination.
We have found that the cancer testis antigen HAGE (DDX43, CT13) is expressed in 43%
of patients with TNBC and that it is an independent predictor of a patient’s response
to chemotherapy. Therefore, patients with HAGE positive tumours might benefit from
a HAGE-specific vaccine.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P06.02
Identification
Copyright
© 2018 Published by Elsevier Inc.
